(Q38122958)

29 August 2017

Somatostatin receptors: from signaling to clinical practice (English)

1 reference

29 August 2017

Marily Theodoropoulou

series ordinal

1

object named as

Marily Theodoropoulou

1 reference

29 August 2017

2

Günter K Stalla

0 references

author name string

Günter K Stalla

series ordinal

2

1 reference

29 August 2017

18 July 2013

1 reference

Frontiers in Neuroendocrinology

29 August 2017

1 reference

29 August 2017

34

1 reference

29 August 2017

3

1 reference

29 August 2017

228-252

1 reference

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin modulates effects of angiotensin II in adrenal glomerulosa zone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Why does somatostatin cause gallstones?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of insulin secretion by somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Peptide receptor targeting in cancer: the somatostatin paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pronostic and Therapeutic Consequences of Gs Mutations in Somatotroph Adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The TOR pathway: a target for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

In vitro antiangiogenic activity of selective somatostatin subtype-1 receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin suppresses secretin and pancreatic exocrine secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Antiproliferative effect of somatostatin and analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin-28: selective action on the pancreatic beta-cell and brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Molecular cloning and functional expression of a brain-specific somatostatin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Binding properties of somatostatin receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Lanreotide for the treatment of acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Deregulated human glioma cell motility: inhibitory effect of somatostatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin dramatically stimulates growth hormone release from primate somatotrophs acting at low doses via somatostatin receptor 5 and cyclic AMP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin analogs for the treatment of neuroendocrine tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype expression and function in human vascular tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of somatostatin analogue SMS 201-995 in normal man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor imaging for neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Tumor imaging and therapy using radiolabeled somatostatin analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The role(s) of somatostatin, structurally related peptides and somatostatin receptors in the gastrointestinal tract: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of genetic SSTR4 ablation on inflammatory peptide and receptor expression in the non-inflamed and inflamed murine intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Acute suppression of insulin and glucose levels by synthetic somatostatin in normal human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: a primary role for tyrosine phosphatase SHP-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characteristics of the interaction between thyrotropin-releasing hormone and somatostatin for thyrotropin and prolactin release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide treatment of acromegaly. A randomized, multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Multiple intracellular effectors modulate physiological functions of the cloned somatostatin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits PC Cl3 thyroid cell proliferation through the modulation of phosphotyrosine activity. Impairment of the somatostatinergic effects by stable expression of E1A viral oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary Adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide treatment does not affect the size of most non-functioning pituitary adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Human somatostatin receptor specificity of backbone-cyclic analogues containing novel sulfur building units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Advances in the treatment of prolactinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Meta-analysis on the effects of octreotide on tumor mass in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Direct inhibition of gastric acid and pepsin secretion by growth-hormone release-inhibiting hormone in cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Actions of growth hormone-release inhibiting hormone (somatostatin) on the renin aldosterone system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits the release of acetylcholine induced electrically in the myenteric plexus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Human ovarian cancers express somatostatin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The pathophysiological consequences of somatostatin receptor internalization and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A nucleotide regulatory site for somatostatin inhibition of adenylate cyclase in S49 lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Human somatostatin receptor, SSTR2, is coupled to adenylyl cyclase in the presence of Gi alpha 1 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin Regulation of Glycoprotein Hormone and Free Subunit Secretion in Clinically Nonfunctioning and Somatotroph Adenomasin Vitro*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Expression cloning of a rat brain somatostatin receptor cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The somatostatin receptor is directly coupled to adenylate cyclase in GH4C1 pituitary cell membranes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of octreotide on glucose tolerance in acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 1 modulates basal inhibition of growth hormone release in somatotrophs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Rat somatostatin receptor subtype 4 can be made sensitive to agonist-induced internalization by mutation of a single threonine (residue 331).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effector coupling of somatostatin receptor subtypes on human endocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Multiple Effector Coupling of Somatostatin Receptor Subtype SSTR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Quantitative in-situ hybridization histochemistry studies on growth hormone (GH) gene expression in acromegalic somatotrophs: effects of somatostatin, GH-releasing factor and cortisol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Conserved motifs in somatostatin, D2-dopamine, and alpha 2B-adrenergic receptors for inhibiting the Na-H exchanger, NHE1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Galpha12 differentially regulates Na+-H+ exchanger isoforms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Caspase-8-mediated intracellular acidification precedes mitochondrial dysfunction in somatostatin-induced apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Identification of the somatostatin receptor subtypes (sst) mediating the divergent, stimulatory/inhibitory actions of somatostatin on growth hormone secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Free Intracellular Ca2+Concentration ([Ca2+]i) and Growth Hormone Release from Purified Rat Somatotrophs. II. Somatostatin Lowers [Ca2+]iby Inhibiting Ca2+Influx*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Medical progress: Acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Guidelines for acromegaly management: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin-induced inhibition of neuronal Ca2+ current modulated by cGMP-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Molecular cloning of a somatostatin-28 receptor and comparison of its expression pattern with that of a somatostatin-14 receptor in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Dopamine receptors: from structure to function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cholelithiasis and acromegaly: therapeutic strategies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The effects of GH-releasing hormone/somatostatin on the 5'-promoter activity of the GH gene in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin A negatively controls the PI3K pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Insulin-like growth factor-I action on growth hormone secretion and messenger ribonucleic acid levels: interaction with somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide as primary therapy for acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The hormonal regulation of food intake, digestion, and absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Yttrium-90-labelled somatostatin-analogue for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of Zac1, a new gene differentially expressed in the anterior pituitary, increases cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

G protein activation of a hormone-stimulated phosphatase in human tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and somatostatin analogues in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and its receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

In vivo and in vitro plasma disappearance and metabolism of somatostatin-28 and somatostatin-14 in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characterization of intracellular signaling mediated by human somatostatin receptor 5: role of the DRY motif and the third intracellular loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Dopamine receptor expression and function in corticotroph pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 4 couples to the M-current to regulate seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of Somatostatin on Gastric Secretion and Gastrin Release in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Prolonged somatostatin pretreatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Immunohistochemical localization of somatostatin receptors sst2A in human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

In vitro detection of somatostatin receptors in human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptors in human prostate and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of Adrenocorticotropin Secretion by Somatostatin in Pituitary Cells in Culture*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cloning and characterization of a fourth human somatostatin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Agonist-induced endocytosis of rat somatostatin receptor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-receptor stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characterization of somatostatin receptor subtypes controlling rat gastric acid and pancreatic amylase release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

On the mechanism of cytosolic phospholipase A2 activation in CHO cells carrying somatostatin receptor: wortmannin-sensitive pathway to activate mitogen-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Brain somatostatin: Receptor-coupled transducing mechanisms and role in cognitive functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pertussis toxin selectively abolishes hormone induced lowering of cytosolic calcium in GH3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide (SOM230): development, mechanism of action and potential applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of somatostatin analogs on glucose homeostasis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The MAPK signaling cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of G(i/o)-coupled somatostatin sst(4) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Receptor isoforms mediate opposing proliferative effects through gbetagamma-activated p38 or Akt pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Ras, PI(3)K and mTOR signalling controls tumour cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin activates an inwardly rectifying K+ conductance in freshly dispersed rat somatotrophs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The pivotal role of phosphoinositide-3 kinase in the human somatostatin sst(4) receptor-mediated stimulation of p44/p42 mitogen-activated protein kinase and extracellular acidification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

N-type Ca(2+) -channels in murine pancreatic beta-cells are inhibited by an exclusive coupling with somatostatin receptor subtype 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide exerts different effects in vivo and in vitro in Cushing's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Physical and functional interactions between protein tyrosine phosphatase alpha, PI 3-kinase, and PKCdelta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Impact of gsp Oncogene on the mRNA Content for Somatostatin and Dopamine Receptors in Human Somatotropinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Regulation of acidification and apoptosis by SHP-1 and Bcl-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

ZAC1 target genes and pituitary tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Transfected human somatostatin receptor type 2, SSTR2, not only inhibits adenylate cyclase but also stimulates phospholipase C and Ca2+ mobilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin inhibits deoxyribonucleic acid synthesis induced by both thyrotropin and insulin-like growth factor-I in FRTL5 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition by somatostatin of ACTH secretion in Nelson's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effects of somatostatin on the secretion of thyrotropin and prolactin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cloning and expression of a novel mouse somatostatin receptor (SSTR2B).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin and the immune and haematopoetic system; a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pituitary adenoma predisposition caused by germline mutations in the AIP gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Opportunities in somatostatin research: biological, chemical and therapeutic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Radiolabeled carbohydrated somatostatin analogs: a review of the current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

First clinical evidence that imaging with somatostatin receptor antagonists is feasible

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Homologous and heterologous desensitisation of somatostatin-induced increases in intracellular Ca2+ and inositol 1,4,5-trisphosphate in CHO-K1 cells expressing human recombinant somatostatin sst5 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

A comparison of the effects of bromocriptine and somatostatin on growth hormone gene expression in the rat anterior pituitary gland in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Hyperpolarization of the membrane potential caused by somatostatin in dissociated human pituitary adenoma cells that secrete growth hormone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin increases voltage-gated K+ currents in GH3 cells through activation of multiple somatostatin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Reconstitution of somatostatin and muscarinic receptor mediated stimulation of K+ channels by isolated GK protein in clonal rat anterior pituitary cell membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

inferred from DOI database lookup

7 January 2021

based on heuristic

1 reference

https://api.crossref.org/works/10.1016%2FJ.YFRNE.2013.07.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YFRNE.2013.07.005

1 reference

29 August 2017

1 reference

PubMed ID

23872332